In addition to acquiring NanoMatrix’s platform technology, intellectual property and commercial-scale equipment, Organogenesis gains NanoMatrix veteran talent, including Gary Cadd, who has already assembled a team within Organogenesis’s
The study deals with the treatment efficacy, cosmetic results and toxicities of patients enrolled in the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial. The trial
Terms of this agreement call for upfront and milestone payments, as well as service fees to ProMetic amounting to $2 million over the next 12 months. Potential revenues
The primary objective for this trial is the evaluation of the safety and tolerability of BNC105. The results obtained from this trial will enable the identification of an
The study showed that, in vitro, NCT clearly demonstrated amoebicidal activity at concentrations that are likely to be well tolerated in humans. Study also reported that co-treatment with
The 200 patient, multi-center, European trial is designed to investigate the safety and efficacy of udenafil, a long acting phosphodiesterase type 5 inhibitor. Dong Hyun Park, president and
The company is seeking approval to manufacture and market the Lo Seasonique for the prevention of pregnancy. The Prescription Drug User Fee Action (PDUFA) date for the Lo
dgd Research of San Antonio, Texas, now a member of Cetero Research, is conducting the Phase IIa, controlled US clinical trial. The trial will enroll a total of
ADVR scientists will be working with the Department of Chemistry and Chemical Biology to identify how compounds such as AVR118, a Phase II clinical candidate, interact with clinically
With Momentum Medical un-audited revenues in excess of $6 million for the year ended December 31, 2007, the addition will create substantial increase in Caribbean American Health Resorts’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.